Is it Time to Go Bottom Fishing With This Cannabis Stock?

Why do you need to buy The Green Organic Dutchman Ltd (TSX:TGOD) stock right now.

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

Green Organic Dutchman (TSX:TGOD) was listed as a public company in April 2018. The euphoria about cannabis legalization in Canada drove TGOD stock from $4.12 in April 2018 to $10.2 in September 2018. However, cannabis stocks have experienced a massive correction in the last 12 months.

Now, TGOD is trading at $2.95 per share, which is 35% above its 52-week low and 71% below its 52-week high. Now, with the next wave of edibles legalization just a few days away, it is possible for cannabis stocks to move higher again, as investor optimism rises. So, do you buy TGOD shares? Let’s have a look at the company’s revenue and earnings growth as well as its valuation to see if it’s a good buy at the current price

Revenue growth is estimated at a staggering 1,843%

Analysts expect TGOD to post revenue of $36.51 million in 2019, a year-over-year growth of 1,843%. Sales are then estimated to rise by 515.5% to $224.71 million in 2020. While still unprofitable, TGOD will be improving the bottom line at a robust rate.

Analysts expect the net margin to improve from -162% in 2019 to 19.2% in 2020. Its EBITDA is estimated to rise from -$43.9 million in 2019 to $106 million in 2021. TGOD is valued at $752.1 million, which is 21 times its 2019 sales and in line with peer cannabis companies.

Why will TGOD become a major cannabis player?

Green Organic Dutchman has raised $465 million to date with a focus on rapid expansion. It has planned manufacturing capacity of 219,000 kg. The company has a 1.47 million square feet of hybrid greenhouses and processing facilities under construction in Canada. It is planning to have 167,000 square feet of manufacturing capacity in Europe and Jamaica.

Similar to other cannabis companies, TGOD will focus on international expansion to drive sales. Its currently focused on gaining traction in Jamaica, Denmark, Poland, and Mexico. TGOD has secured licensing deals in Canada and international markets and has a vibrant consumer-driven product portfolio.

The company has valued the medical market at $758 million and the recreational market at $5.7 billion.

Strong distribution network

TGOD has partnered with Velvet Management Inc., which is a leading cannabis sales and marketing agency. Velvet Management was established by Philippe Dandurand Wines, which is the largest wine distributor in Canada.

TGOD recently completed its first supply order to the Ontario Retail Cannabis Corp. It has supply agreements with The BC Liquor Distribution Branch and The Alberta Gaming, Liquor & Cannabis Commission.

The biggest driver for TGOD sales will be its entry into the U.S. markets next year. It has partnered with billion-dollar ingredient heavyweight Symrise to create Califormulations which is a U.S.-based beverage innovation company. Symrise provides companies with beverage commercialization support, technical services, and contract manufacturing co-ordination services.

It has also partnered with Jamaican market leader Epican Medicinals. The latter is a vertically integrated company with licences for cultivation, extraction, manufacturing, and retail distribution of cannabis products.

The verdict

While it might seem like TGOD is just another unprofitable high growth cannabis company, it is growing sales at an astounding rate via partnerships. It is expected to be profitable in the near future. TGOD is a good bet, as it seems that cannabis stocks should move higher significantly, at least till edibles are legalized.

Analysts have a 12-month price target of $5.23 for TGOD. This indicates that the stock is trading at a discount of 77% to the average target estimate.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »